Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.
about
Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival ratesCombined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer - a Retrospective AnalysisRadiofrequency ablation as a treatment strategy for liver metastases from breast cancer.In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver.Surgical management of breast cancer liver metastasesOligometastatic breast cancer: a shift from palliative to potentially curative treatment?Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines.Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated PatientsSerological diagnosis of liver metastasis in patients with breast cancer.Primary or metastatic hepatic carcinoma? A breast cancer patient after adjuvant chemotherapy and radiotherapy postoperatively with intrahepatic cholangiocarcinoma and review of the literature.A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver.PAR1 is selectively over expressed in high grade breast cancer patients: a cohort studyImprovement of survival and prospect of cure in patients with metastatic breast cancer.Prognostic factors and survival in metastatic breast cancer: A single institution experience.Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial.Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance.Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters.Making the Case: Intra-arterial Therapy for Less Common Metastases.Expression of cell polarity protein scribble differently affects prognosis in primary tumor and lymph node metastasis of breast cancer patients.Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer.Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report.Intraarterial Liver-Directed Therapies: The Role of Interventional Oncology.One shot of carbon-ion radiotherapy cured a 6-cm chemo-resistant metastatic liver tumor: a case of breast cancer.Doxorubicin-Loaded 70-150 μm Microspheres for Liver-Dominant Metastatic Breast Cancer: Results and Outcomes of a Pilot Study.Surgery for liver metastases from breast cancer.Q57138814Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastases
P2860
Q30657649-B3A022F5-9B51-484A-8299-71A9CE59DF7EQ30872798-9097873D-51F3-495A-93E9-1B742CF77336Q34284297-09E0F1F1-7D44-43D3-8A08-339BCCD02888Q34563919-5D3240F9-FBE3-42DA-972C-CA333691C5A7Q34711966-0CD3C3EC-D285-4F3F-99FD-37933DEE8AE7Q34846333-306A80D6-3088-4102-9DC4-71BD4BB5BAB7Q35164247-DAABB887-9619-487D-AC8E-26F6304E2DEBQ36482781-EFD8511F-CBF5-410E-A68F-601BD231C8ACQ36616289-4C96DFC4-731C-4B86-A4B9-302B4176B5E2Q36757904-A98791F6-2986-45C8-AB4A-2DCCDE508284Q36814331-6AB020BC-A312-429D-9C3F-1C6E0C30D92EQ37096940-2BA4F588-5D96-470A-9B4D-C8F4CCCC9498Q37216654-AC1E492D-9077-4EE2-8DCB-4B840E2B6613Q37246397-D0C6E11A-43D8-46FB-94F2-7EA34340AB6BQ37386277-15B1F10A-00D9-4F40-84ED-CE42507F755EQ37392167-9CBE34E3-4DD0-4790-8395-1B435E1908B2Q37427057-CD27C91A-17D2-4843-9B02-2A08F10223A3Q37709855-DBC56CC2-AF8C-439E-B30D-5BA125B1E311Q38711196-34FE308D-29DB-45E9-B00C-57D7826A498DQ38745186-94364AFC-0F74-4084-91DF-9E6E369A4B85Q40606844-8A71F171-EDC3-46C7-AA2E-BBD31F181C3EQ41603527-B715044E-23EE-424F-A85E-E90F1FAE588BQ41711634-1B8F9BD0-EB10-41A3-9A39-B566A85BAFCBQ47101871-CEAB15F9-5B35-4FD9-A22B-CBE92A80506EQ48153351-4DC31DC0-97F4-4819-841E-2249314E5EFCQ51159127-9210C3A6-D0F4-46FA-8E97-49DBC32F855BQ53511230-B84E50FE-C560-4911-B823-49FA2F696E55Q57138814-5BD695B1-05DE-43BB-B91C-50915CED6317Q57781463-B3F074FB-6C8E-4829-8000-690238F1A1DA
P2860
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Clinical outcome of breast can ...... tastatic breast cancer trials.
@ast
Clinical outcome of breast can ...... tastatic breast cancer trials.
@en
type
label
Clinical outcome of breast can ...... tastatic breast cancer trials.
@ast
Clinical outcome of breast can ...... tastatic breast cancer trials.
@en
prefLabel
Clinical outcome of breast can ...... tastatic breast cancer trials.
@ast
Clinical outcome of breast can ...... tastatic breast cancer trials.
@en
P2093
P1476
Clinical outcome of breast can ...... tastatic breast cancer trials.
@en
P2093
A H Calvert
A Minisini
EORTC Breast Cancer and Early Clinical Studies Groups
L Biganzoli
M J Piccart
P Therasse
R Paridaens
P304
P356
10.1016/S0959-8049(03)00601-4
P577
2003-11-01T00:00:00Z